The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.
 
Kirsten Fischer
Travel, Accommodations, Expenses - Roche
 
Othman Al-Sawaf
Other Relationship - Abbvie; Gilead Sciences; Janssen; Roche
 
Jasmin Bahlo
Honoraria - Roche
Travel, Accommodations, Expenses - Roche
 
Anna-Maria Fink
Consulting or Advisory Role - Janssen
 
Maneesh Tandon
Employment - Roche
 
Mark Dixon
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Sandra Robrecht
No Relationships to Disclose
 
Kathryn Humphrey
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Sebastian Böttcher
Honoraria - Abbvie; Janssen; Roche
Research Funding - Abbvie; Celgene; Janssen; Roche
Other Relationship - Abbvie; Janssen
 
Eugen Tausch
Consulting or Advisory Role - Roche
Speakers' Bureau - Roche
Expert Testimony - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Rod Humerickhouse
Employment - AbbVie
Stock and Other Ownership Interests - Abbvie
 
Barbara Eichhorst
Honoraria - Abbvie; Celgene; Gilead Sciences; Janssen-Cilag; Novartis; Roche
Consulting or Advisory Role - Abbvie; Gilead Sciences; Janssen-Cilag; Novartis; Roche
Speakers' Bureau - Abbvie; Celgene; Gilead Sciences; Janssen-Cilag; Roche/Genentech
Research Funding - Abbvie; Gilead Sciences; Janssen; Roche
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Janssen; Roche
 
Clemens-Martin Wendtner
Honoraria - Abbvie; Gilead Sciences; Janssen-Cilag; MorphoSys; Mundipharma; Novartis; Roche
Research Funding - Abbvie; Gilead Sciences; Janssen-Cilag; MorphoSys; Mundipharma; Novartis; Roche
 
Anton W. Langerak
Consulting or Advisory Role - Abbvie (Inst)
Research Funding - Gilead Sciences (Inst); Roche/Genentech (Inst)
 
Karl-Anton Kreuzer
Consulting or Advisory Role - Abbvie; Roche
Expert Testimony - Abbvie; Roche
 
Valentin Goede
Consulting or Advisory Role - Abbvie; Gilead Sciences; Janssen; Roche
Speakers' Bureau - Gilead Sciences; Janssen; Roche
 
Stephan Stilgenbauer
Honoraria - AbbVie, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen,
Consulting or Advisory Role - AbbVie, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen,
Speakers' Bureau - AbbVie, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen,
Research Funding - AbbVie, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen,
Travel, Accommodations, Expenses - AbbVie, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen,
 
Mehrdad Mobasher
Employment - Corvus Pharmaceuticals; Genentech
Leadership - Corvus Pharmaceuticals
Stock and Other Ownership Interests - Corvus Pharmaceuticals; Roche
Research Funding - Corvus Pharmaceuticals; Genentech
Travel, Accommodations, Expenses - Corvus Pharmaceuticals; Genentech
 
Matthias Ritgen
Consulting or Advisory Role - Abbvie; Roche
Research Funding - Abbvie; Roche
Other Relationship - Roche
 
Michael J. Hallek
Honoraria - Abbvie; Gilead Sciences; Janssen; Roche
Consulting or Advisory Role - Abbvie; Genentech/Roche; Gilead Sciences; Janssen
Speakers' Bureau - Abbvie; Gilead Sciences; Janssen; Roche/Genentech
Research Funding - Abbvie; Gilead Sciences; Janssen; Roche
Travel, Accommodations, Expenses - Janssen; Roche